TNGX
Tango Therapeutics Inc.
Company Overview
| Mkt Cap | $1.05B | Price | $9.35 |
| Volume | 2.62M | Change | +2.75% |
| P/E Ratio | -8.0 | Open | $9.10 |
| Revenue | $42.1M | Prev Close | $9.10 |
| Net Income | $-130.3M | 52W Range | $1.03 - $11.20 |
| Div Yield | N/A | Target | $13.22 |
| Overall | 46 | Value | 45 |
| Quality | 44 | Technical | 50 |
No chart data available
About Tango Therapeutics Inc.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors; TNG462, which is in Phase 1/2 clinical trial for non- central nervous system cancers including pancreatic and lung cancer; TNG456, a brain-penetrant PRMT5 inhibitor, for central nervous system cancers including glioblastoma; and TNG260, a co-repressor of repressor element-1 silencing transcription (CoREST) inhibitor to reverse the immune evasion effect of STK11 loss-of-function mutations. The company has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
Latest News
Tango Therapeutics Enters New Sales Agreement with Leerink
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TNGX | $9.35 | +2.7% | 2.62M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |